First Trust Advisors
PTGX icon

First Trust Advisors’s Protagonist Therapeutics PTGX Stock Holding History

First Trust Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.26M Buy
87,858
+41,404
+89% +$3.67M 0.01% 1135
2025
Q4 		$4.06M Sell
46,454
-16,270
-26% -$1.33M ﹤0.01% 1517
2025
Q3 		$4.17M Sell
62,724
-51,183
-45% -$2.91M ﹤0.01% 1472
2025
Q2 		$6.3M Buy
113,907
+32,221
+39% +$1.55M 0.01% 1258
2025
Q1 		$3.95M Sell
81,686
-59,265
-42% -$2.48M ﹤0.01% 1432
2024
Q4 		$5.44M Buy
140,951
+27
+0% +$1.18K ﹤0.01% 1315
2024
Q3 		$6.34M Buy
140,924
+9,114
+7% +$368K 0.01% 1218
2024
Q2 		$4.57M Buy
131,810
+71,147
+117% +$2.08M ﹤0.01% 1307
2024
Q1 		$1.75M Buy
+60,663
New +$1.65M ﹤0.01% 1791
2022
Q3 		– Sell
-14,328
Closed -$113K – 2583
2022
Q2 		$113K Sell
14,328
-27,444
-66% -$332K ﹤0.01% 2450
2022
Q1 		$989K Buy
+41,772
New +$1.18M ﹤0.01% 2047

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

First Trust Advisors's PTGX Position: Q1 2026 in Review

First Trust Advisors increased its Protagonist Therapeutics (PTGX) stake by 89% in Q1 2026, buying an estimated $3.67M and bringing the position to 87,858 shares worth $9.26M. The position accounts for 0.01% of the portfolio, ranked #1135.

First Trust Advisors first reported a position in PTGX in Q1 2022 and has held it in 11 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • First Trust Advisors held 87,858 shares of Protagonist Therapeutics worth $9.26M as of Q1 2026.
  • First Trust Advisors bought 41,404 Protagonist Therapeutics shares in Q1 2026, an estimated $3.67M.
  • Protagonist Therapeutics made up 0.01% of First Trust Advisors's portfolio in Q1 2026, its #1135 holding.
  • First Trust Advisors first reported a position in Protagonist Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.